Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: Report of two cases

Ramos, Francisco Javier Melgosa; Ruiz, Ramón García; Puchades, Almudena Mateu

doi:10.1111/dth.15266

Cited by 10 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six of nine patients with relevant data available achieved HiSCR in a case series of patients who received golimumab [ 37 ]. Three out of four additional patients have improved [ 38 – 40 ].…”

Section: Resultsmentioning

confidence: 99%

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies

Fragoso,

Masson,

Gillenwater

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is an oftentimes debilitating condition that presents with painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part because the pathogenesis of the condition is incompletely understood but also because there are limited therapeutic options. HS research is undergoing explosive growth with multiple new molecular pathways under study, which will hopefully lead to improved disease control for patients. Part I of this review will provide an overview of the emerging topical and systemic therapies under investigation for HS.

show abstract

Section: Resultsmentioning

confidence: 99%

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies

Fragoso,

Masson,

Gillenwater

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…In one patient, 50 mg of golimumab monthly did not result in a clinical improvement in HS [105]. In the other three patients, a higher dosage of golimumab (200 mg followed by 100 mg monthly) showed brilliant results with a decrease in IHS4 [106,107]. Golimumab could be an alternative therapy in HS, especially in those with HS-associated inflammatory arthritis and adalimumab failure, as patients show improvement in both diseases [107] (Table 1).…”

Section: Golimumabmentioning

confidence: 97%

New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa

Molinelli

Gioacchini

Sapigni

et al. 2023

IJMS

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is an immune-mediated inflammatory disorder characterized by deep-seated nodules, abscesses, sinus tracts and scars localized in the intertriginous areas. It is accompanied by pain, malodourous secretion and a dramatically decreased quality of life. Although the pathogenesis has not been entirely elucidated, the primary event is follicular hyperkeratosis of the pilosebaceous apocrine unit. Since the registration of the tumor necrosis factor-alpha inhibitor Adalimumab in 2015, several cytokines have been implicated in the pathomechanism of HS and the research of novel therapeutic targets has been intensified. We provide an update on the inflammatory cytokines with a central role in HS pathogenesis and the most promising target molecules of future HS management.

show abstract

“…Smaller studies have reported varying degrees of success in using golimumab. Ramos et al reported success in using golimumab in two patients with HS and arthritis after treatment failure with adalimumab [73]. In another retrospective cohort study evaluating golimumab use in thirteen patients with severe and recalcitrant HS previously failing adalimumab and infliximab, six out of nine patients who have available data for HiSCR calculation achieved this.…”

Section: Golimumabmentioning

confidence: 98%

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa

Chen,

Guo,

Petty

et al. 2024

Immuno

View full text Add to dashboard Cite

Hidradenitis Suppurativa (HS) is a debilitating cutaneous disease characterized by a vicious cycle of chronic inflammation and tissue destruction that stems from disruption of the skin microbiome and abnormal activation of both the innate and adaptive immune system. A hallmark of HS pathophysiology is dysregulation of both the innate and adaptive immune system. The role of immune system dysregulation in HS development has motivated researchers to explore the utility of biologic immunomodulators. In 2015, adalimumab, a tumor necrosis factor-α inhibitor, was approved by the Food and Drug Administration (FDA) for treatment of moderate-to-severe HS in the US. In 2023, secukinumab, an interleukin-17A (IL-17A) inhibitor, was approved by the European Medicines Agency for treatment of moderate-to-severe HS in Europe. Ongoing clinical trials have shown promising clinical responses to targeted therapies against other pro-inflammatory cytokines including IL-17, IL-12, IL-1, IL-36, IL-6, IL-10, interferon γ, C5a, and Janus kinase (JAK). We provide an update on the efficacy and clinical usage of targeted biologics in HS treatment.

show abstract

Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: Report of two cases

Cited by 10 publications

References 6 publications

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies

New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa

Contact Info

Product

Resources

About